Overview

A Study of BGB-A445 in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer

Status:
Recruiting
Trial end date:
2026-05-01
Target enrollment:
Participant gender:
Summary
The main objective of this study is to evaluate the anti-tumor activity of BGB-A445 plus investigational agents in participants with non-small cell lung cancer (NSCLC)
Phase:
Phase 2
Details
Lead Sponsor:
BeiGene
Treatments:
Docetaxel
Ramucirumab